Project Grant R01DK143883
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Northwestern University $794,032 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate mechanisms of intestinal barrier dysfunction in people living with HIV on antiretroviral therapy and to evaluate restoration of the glycan A1,2-fucose as a therapeutic intervention. The research addresses persistent gut leakiness and microbial translocation in...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Texas Biomedical Research Institute $905,998 on September 1, 2026, to investigate epigenetic mechanisms driving intestinal epithelial dysfunction in people living with HIV receiving antiretroviral therapy, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research examines how aberrant DNA methylation and altered chromatin accessibility in colonic epithelium contribute...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Northwestern University $811,941 on September 3, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop three-dimensional intestinal organoid models that investigate the bidirectional relationship between HIV transcription and intestinal barrier function in people living with HIV. The research uses complementary organoid platforms: patient-derived organoids isolated...
- The National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health within the Department of Health and Human Services, awarded $5.296987 million to the Regents of the University of Minnesota on September 16, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The recipient will investigate HIV reservoir dynamics and their association with metabolic complications in people with HIV on antiretroviral...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Administrators of Tulane Educational Fund (doing business as Tulane University) $673,261 on August 10, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate hematopoietic stem cell response to chronic liver disease and their role in systemic inflammation. The research addresses mechanisms by which chronic liver injury disrupts bone marrow homeostasis,...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Baylor College of Medicine $240,000 on August 27, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop preclinical mouse models expressing HIV proteins that replicate metabolic comorbidities observed in persons living with HIV, including obesity, cardiovascular disease, chronic kidney disease, osteoporosis, cancers, frailty, and cognitive decline. The research...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded the University of Illinois $882,709 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate adipose tissue dysfunction in simian immunodeficiency virus (SIV)-infected rhesus macaques treated with combination antiretroviral therapy (cART). The research addresses lipodystrophy and metabolic complications that affect over 75% of chronic HIV...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Tulane University $1,226,298 on September 24, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate epigenetic control of nephron progenitor cell lifespan in mice and humans. The research addresses the cessation of nephrogenesis at birth, which eliminates the opportunity to generate new nephrons following congenital or acquired loss of renal mass. The project...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Texas Health Science Center at Houston $154,332 on March 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of kynurenine-aryl hydrocarbon receptor signaling in cholestatic liver injury. The research examines how the kynurenine pathway and aryl hydrocarbon receptor activation regulate reactive oxygen species accumulation,...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Duke University $832,783 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on February 1, 2026, to define cellular and molecular signatures of inflammation in people with HIV on antiretroviral therapy that promote chronic kidney disease. The research employs a dual-cohort approach: retrospective analysis of plasma inflammatory endotypes in aging people with HIV (age 50 and...
The National Institute of Diabetes and Digestive and Kidney Diseases awarded Tulane University $840,005 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of aryl hydrocarbon receptor (AHR) signaling in intestinal barrier function and inflammation during antiretroviral therapy-suppressed simian immunodeficiency virus infection. The research defines how gut AHR signaling preserves epithelial barrier integrity and restrains systemic inflammation in chronically infected rhesus macaques, and tests whether therapeutic activation of AHR signaling through exogenous ligands and in vivo gamma-delta T cell stimulation can restore gut barrier function by enhancing the AHR-IL-22 immune axis. The work addresses a core mechanism linking chronic viral infection, intestinal epithelial barrier disruption, microbial translocation, and systemic inflammation in people living with HIV who experience incomplete immune restoration despite effective viral control. Work is performed in Covington, Louisiana, with a period of performance from September 1, 2026, through July 31, 2031. The award is structured as a Project Grant, the standard assistance type for NIH R01 awards.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $840.0k | 8/31/26 |